FRE.DE - Fresenius SE & Co. KGaA

XETRA - XETRA Delayed price. Currency in EUR
42.83
+0.56 (+1.32%)
At close: 5:35PM CEST
Stock chart is not supported by your current browser
Previous close42.27
Open42.50
Bid42.76 x 120700
Ask42.79 x 6100
Day's range42.06 - 43.17
52-week range24.25 - 51.54
Volume1,597,712
Avg. volume1,825,052
Market cap28.383B
Beta (5Y monthly)1.17
PE ratio (TTM)13.06
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield0.84 (1.99%)
Ex-dividend date31 Aug 2020
1y target estN/A
  • Reuters

    Fresenius beats second-quarter earnings forecasts, cuts 2020 outlook

    The group said its separately listed dialysis unit, Fresenius Medical Care, showed very strong earnings growth and exceptional cash flow in the quarter. For 2020, Fresenius expects adjusted net income change between a negative 4% and a positive 1%, and revenue growth in the range of 3% to 6%, compared to its previous forecast for growth between 1% to 5% and 4% to 7%, respectively, which did not account for the pandemic's effects. Fresenius' second-quarter net income came in at 410 million euros ($482.6 million), above analysts' average forecast of 398 million euros, according to a company-provided poll.

  • Fresenius cuts 2020 outlook on pandemic impact
    Reuters

    Fresenius cuts 2020 outlook on pandemic impact

    In its first forecasts factoring in the impact of the pandemic, the company said it expected adjusted net income this year within a range of down 4% to up 1% from last year, and revenue growth of 3-6%. The pandemic has been a mixed blessing for healthcare companies, bringing increased demand for selected products and services but also delays in treatments and extra expenses. While the number of post-acute treatments should gradually recover, postponed site inspections will cut Fresenius' 2020 product launches by about 30% and project delays may last well into the second half, Sturm said.

  • Should Value Investors Buy Fresenius (FMS) Stock?
    Zacks

    Should Value Investors Buy Fresenius (FMS) Stock?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • FMS vs. ABMD: Which Stock Should Value Investors Buy Now?
    Zacks

    FMS vs. ABMD: Which Stock Should Value Investors Buy Now?

    FMS vs. ABMD: Which Stock Is the Better Value Option?

  • Should Value Investors Buy FRESENIUS SECO (FSNUY) Stock?
    Zacks

    Should Value Investors Buy FRESENIUS SECO (FSNUY) Stock?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • Analysts upbeat on the outlook for Fresenius Se amp; Co Kgaa
    Stockopedia

    Analysts upbeat on the outlook for Fresenius Se amp; Co Kgaa

    The Fresenius Se amp;amp; Co Kgaa (ETR:FRE) share price has risen by 5.87% over the past month and it’s currently trading at 43.66. For investors considering...

  • Two factors that could move the Fresenius Se amp; Co Kgaa (ETR:FRE) share price
    Stockopedia

    Two factors that could move the Fresenius Se amp; Co Kgaa (ETR:FRE) share price

    The Fresenius Se amp;amp; Co Kgaa (ETR:FRE) share price is currently trading at 43.97. But given the volatile market conditions and uncertain economic outlook...

  • WeWork Board Factions Head for Clash Over New Directors
    Bloomberg

    WeWork Board Factions Head for Clash Over New Directors

    (Bloomberg) -- WeWork’s board is scheduled to vote on appointing two new directors on Friday, a critical step in a clash between shareholder SoftBank Group Corp. and a rival faction at the troubled co-working startup.A lawyer for WeWork told Delaware Chancery Court Judge Andre Bouchard in a letter that the company plans a May 29 meeting to fill two empty independent director seats. The nominees are Alex Dimitrief, General Electric Co.’s ex-top lawyer, and Frederick Arnold, the former chief financial officer for Convergex Group.SoftBank and the rival board faction are feuding over the Japanese conglomerate’s decision to scrap a $3 billion deal to buy stock from WeWork’s former Chief Executive Officer Adam Neumann and other shareholders. SoftBank agreed to the purchase last year as it bailed out the struggling startup, but then notified stockholders in March that some of the deal’s conditions hadn’t been met.Two independent WeWork directors then sued SoftBank for not following through on the transaction. One of them, Bruce Dunlevie, is a partner at the venture firm Benchmark Capital, which had planned on selling WeWork shares to SoftBank as part of the agreement.The new directors, who are expected to butt heads with the pair who filed the suit, will be on a special board committee tasked with deciding whether Dunlevie and another board member, Lew Frankfort, can properly represent the company in the SoftBank suit.In a court hearing Wednesday, Bouchard rejected bids by Dunlevie and Frankfort to block WeWork from adding new directors. Dunlevie and Frankfort were the only members of the earlier special committee that made the decision to sue. They had sought a so-called “status quo” order to maintain the company’s operations during the SoftBank litigation.“We believe SoftBank has no basis to question the special committee’s authority to bring this action and we are pleased by the court’s recognition that any effort by SoftBank to challenge that authority must be presented” to Bouchard, a spokesman for Dunlevie and Frankfort said Wednesday.SoftBank-backed WeWork officials said they are acting in the best interest of the company.“WeWork is pursuing best practices of corporate governance to determine what role if any WeWork should have in this contractual dispute among its shareholders,” Sarah Lubman, a SoftBank spokeswoman, said in an emailed statement. “The court’s decision today allows that process to go forward.”In their suit, Dunlevie and Frankfort contend SoftBank had “buyer’s remorse” and reneged on promises to “use its reasonable best efforts to consummate” the stock-purchase agreement.They also noted the agreement doesn’t contain a so-called “material adverse effect” provision or similar termination right that is common in such deals. Two years ago, a Delaware judge found such a provision permitted Germany’s Fresenius SE to walk away from its takeover of U.S. rival generic drugmaker Akorn Inc.In a message to shareholders in March, Softbank cited nearly a half-dozen conditions for the deal that WeWork officials hadn’t met, including a failure to renegotiate some leases in the wake of the economic havoc caused by the Covid-19 pandemic.Neumann -- who would have reaped the biggest windfall from the deal -- filed his own suit earlier this month claiming SoftBank is relying on legally faulty pretexts to scuttle the deal.The dispute is among several busted-deal cases tied to Covid-19 that landed in Delaware’s business court. The state is the corporate home to more than half of U.S. public companies and more than 60% of Fortune 500 firms. Chancery judges hear cases without juries and can’t award punitive damages.Dunlevie’s and Frankfort’s suit is The We Company v. SoftBank Group Corp, No. 2020-0258, Delaware Chancery Court (Wilmington). Neumann’s case is Neumann v. SoftBank Group Corp, Delaware Chancery Court.(Updates with judge’s denial of status-quo order in sixth paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • Brokers upbeat on Fresenius Se amp; Co Kgaa despite economic uncertainty
    Stockopedia

    Brokers upbeat on Fresenius Se amp; Co Kgaa despite economic uncertainty

    The Fresenius Se amp;amp; Co Kgaa (ETR:FRE) share price has risen by 5.63% over the past month and it’s currently trading at 39.94. For investors considering...

  • Results: Fresenius SE & Co. KGaA Beat Earnings Expectations And Analysts Now Have New Forecasts
    Simply Wall St.

    Results: Fresenius SE & Co. KGaA Beat Earnings Expectations And Analysts Now Have New Forecasts

    Fresenius SE & Co. KGaA (ETR:FRE) defied analyst predictions to release its quarterly results, which were ahead of...

  • Fresenius reports first-quarter net income beat on pandemic demand
    Reuters

    Fresenius reports first-quarter net income beat on pandemic demand

    Healthcare companies worldwide have benefited from subsidies and increased demand as a result of the coronavirus crisis, but they have also faced new costs, including protective gear. Fresenius' first-quarter net income was 465 million euros ($503.97 million), above analysts' average forecast of 421.8 million euros, a Refinitiv poll found. "It is, however, too early to say with any certainty what impact COVID-19 will have on the company's full business year," Chief Executive Stephan Sturm said in a statement.

  • Is Fresenius (FMS) a Great Value Stock Right Now?
    Zacks

    Is Fresenius (FMS) a Great Value Stock Right Now?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • Upbeat broker recommendations for Fresenius Se amp; Co Kgaa
    Stockopedia

    Upbeat broker recommendations for Fresenius Se amp; Co Kgaa

    The Fresenius Se amp;amp; Co Kgaa (ETR:FRE) share price has risen by 18.5% over the past month and it’s currently trading at 40.18. For investors considering8230;

  • Should You Like Fresenius SE & Co. KGaA’s (ETR:FRE) High Return On Capital Employed?
    Simply Wall St.

    Should You Like Fresenius SE & Co. KGaA’s (ETR:FRE) High Return On Capital Employed?

    Today we'll evaluate Fresenius SE & Co. KGaA (ETR:FRE) to determine whether it could have potential as an investment...

  • WeWork Directors Sue SoftBank Over Decision to Abandon Deal
    Bloomberg

    WeWork Directors Sue SoftBank Over Decision to Abandon Deal

    (Bloomberg) -- Two independent WeWork directors sued SoftBank Group Corp., its biggest shareholder, after the Japanese investor scrapped a $3 billion deal to buy stock from ex-Chief Executive Officer Adam Neumann and other shareholders to bail out the struggling workplace provider.SoftBank reneged on promises to “use its reasonable best efforts to consummate” the stock-purchase agreement because of “buyer’s remorse,” the directors, which make up a special committee of WeWork’s board, said in the Delaware Chancery Court lawsuit.“Instead of abiding by its contractual obligations, SoftBank, under increasing pressure from activist investors, has engaged in a purposeful campaign to avoid completion of the tender offer,” said Bruce Dunlevie and Lew Frankfort, who make up the committee. The pair regret “the fact SoftBank continues to put its own interests ahead of those of WeWork’s minority stockholders,” according to an emailed statement.A spokesperson for SoftBank said it would vigorously defend the lawsuit. “Nothing in the special committee’s filing today credibly refutes SoftBank’s decision to terminate the tender offer,” the spokesperson said Tuesday in a statement. Softbank said several conditions for completing the tender were not met and called the special committee’s filing a “desperate and misguided attempt” to revise history.“The Special Committee will not prevail in this mistaken attempt to force SoftBank to purchase their shares when it is not legally obligated to do so,” the spokesperson said.Paul Singer’s Elliott Management Corp., a major investor in Softbank, has advocated for the Japanese company to boost its own value by engaging in stock buybacks.Bailout PackageSoftBank agreed to buy shares from Neumann, Benchmark Capital and others as part of a bailout package last year, but notified stockholders in mid-March that some of the deal’s conditions hadn’t been met. After the deal’s closing deadline passed last week, SoftBank confirmed it was pulling the offer.In a message to shareholders last month, Softbank cited nearly a half-dozen conditions that WeWork officials hadn’t met as the basis for pulling out of purchase, including its failure to renegotiate some leases in the wake of the economic havoc caused by the Covid-19 pandemic. Of the tender offer, $450 million is currently allocated to current and former employees, according to a person with knowledge of the matter.The directors pointed to efforts by SoftBank executives to “thwart” a consolidation of WeWork’s Chinese joint venture as evidence that they had second thoughts about the deal. Softbank cited the failure to complete the “roll-up” of the China unit as one of the conditions that hadn’t been met, while WeWork executives accused their erstwhile partner of creating a pretext for pulling out of the agreement.Softbank’s argument that WeWork failed to gain the necessary regulatory approvals for the deal also doesn’t fly because the only country left to sign off on the transaction was Mexico and WeWork has until August to gain that country’s okay, according to the suit.“SoftBank’s apparent buyer’s remorse” was spurred by its own declining financial condition, the WeWork directors said in the suit. “SoftBank’s enormous and growing debt burden, which is now over $109 billion, led Moody’s to issue a rare two-notch downgrade in SoftBank’s debt rating in March 2020,” according to the suit.‘Material Adverse Effect’The directors also noted the agreement doesn’t contain a so-called “material adverse effect” provision or similar termination right that is common in such deals. Two years ago, a Delaware judge found such a provision permitted Germany’s Fresenius SE to walk away from its takeover of U.S. rival generic drugmaker Akorn Inc.The WeWork directors want a chancery judge to order Softbank to carry out the stock purchase and acknowledge it trampled on the rights of some investors in the workplace provider. “SoftBank’s actions harmed the company’s minority stockholders by depriving them of liquidity, which was the primary consideration they were to receive under” the agreement, the suit said.The suit was filed in Delaware because it’s the corporate home to WeWork and more than half of U.S. public companies.The case is The We Company v. Softbank Group Corp, No. 2020-0258, Delaware Chancery Court (Wilmington)(Adds comment from Softbank in fourth and fifth paragraphs)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • Reuters - UK Focus

    Italy looks to safeguard biomedical valley leading fight against COVID-19

    Italy plans to tighten health checks to ensure that work is not disrupted in a small northern town specialising in the production of medical supplies to tackle its coronavirus crisis. The area snuggled around the medieval town of Mirandola has become a focus for desperate health authorities seeking to source equipment in the European country where COVID-19 has taken the most deadly toll. "This is a key strategic sector that we need to nurture and we're going to make sure it stays open for business," said Sergio Venturi, coronavirus czar for the northern region of Emilia Romagna where Mirandola is located.

  • What Is Fresenius SE KGaA's (ETR:FRE) P/E Ratio After Its Share Price Tanked?
    Simply Wall St.

    What Is Fresenius SE KGaA's (ETR:FRE) P/E Ratio After Its Share Price Tanked?

    To the annoyance of some shareholders, Fresenius SE KGaA (ETR:FRE) shares are down a considerable 35% in the last...

  • Fresenius SE & Co. KGaA Full-Year Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
    Simply Wall St.

    Fresenius SE & Co. KGaA Full-Year Results Just Came Out: Here's What Analysts Are Forecasting For Next Year

    It's been a good week for Fresenius SE & Co. KGaA (ETR:FRE) shareholders, because the company has just released its...

  • Fresenius forecasts 2020 profit growth driven by drug, dialysis units
    Reuters

    Fresenius forecasts 2020 profit growth driven by drug, dialysis units

    Following a tumultuous 2018 when Fresenius issued several profit warnings, last year was marked by investment and stabilisation, with the group's management pointing to an improvement from 2020 onwards. Separately-listed dialysis unit Fresenius Medical Care <FMEG.DE>, which generated 49% of the group's quarterly revenue, on Wednesday reported in-line results saying record growth in home care dialysis offset the one-off effects of an ongoing legal dispute. Home care has been a growth area for the world's largest kidney dialysis provider, but it has been critical of hard targets set by President Donald Trump's administration for treating more patients with kidney disease at home.

  • Bingeing Alone Isn’t Enough for Nestle
    Bloomberg

    Bingeing Alone Isn’t Enough for Nestle

    (Bloomberg Opinion) -- It isn’t just Unilever NV that’s struggling to sell more food. Rival Nestle SA now expects to come up short of its self-imposed sales-growth target this year, and it’s counting on acquisitions to put it back on track.While Chief Executive Officer Mark Schneider met the lower end of  a goal for underlying operating margin 12 months early, it will take at least another year for the owner of the Nesquik and Nespresso brands to reach and sustain its annual sales growth objective of 4-6%, partly due to the effect of disposals.It’s a rare misstep for Nestle’s first external CEO for almost 100 years. Even with the 2% drop on Thursday, the shares are up more than 40% since his arrival in January 2017, outpacing Unilever. While Schneider’s made a good start selling off underperformers and making purchases in faster growing areas, such as coffee, pet food and meat substitutes, more reshaping is needed. He has traded — either acquired or moved  out of — businesses that accounted for about 12% of total sales in 2017. That’s ahead of his target for changing up 10% by the end of 2020. He’s not done yet. From here the focus will be more on acquisitions than disposals.While expanding in the right growth markets is key, Schneider should also go further in pruning the Swiss food giant. Possible culprits for offloading could be parts of the U.S. frozen foods business, especially pizzas, or some water assets, such as those mainstream brands that can’t be taken up market. The fact that Nestle wrote down the value of its Yinlu business in China could be a prelude to an exit from difficult divisions, for example making peanut milk. However, selling off these businesses may be trickier than previous disposals in confectionery, skincare and ice cream.There’s also a risk that Schneider, in an effort to turbocharge growth, becomes less disciplined when he buys. He indicated that he’s open to a wide array of options, the most promising being small or mid-sized purchases, particularly in the hot market for nutrition and metabolism. He lamented that last year was heavy on disposals, but light on purchases. That should change this year, but he shouldn’t be too eager and so strike rash deals.Schneider is comfortable in the pharmaceutical space, having led German healthcare company Fresenius SE before joining Nestle. Medical nutrition not only has higher growth prospects and margins than many food areas, but it is also less constrained by competition rules because Nestle doesn’t have such a big position. He most recently bolstered Nestle’s medical nutrition arm by acquiring gastrointestinal medication Zenpep and increased the investment in Aimmune Therapeutics Inc., which has developed a product to counter the effects of peanut allergies. It indicates that this area, particularly treatments related to the body’s metabolism, is likely to be a bigger focus.To fund any large-scale ambitions, Schneider has Nestle’s stake in L’Oreal SA, worth about 35 billion euros ($38 billion), to play with. The company has always said that it won’t part with this holding unless it has a strategic use for the proceeds, but but he seemed to be more open to an exit on Thursday. Small- to medium-sized deals wouldn’t require any change. A bigger transaction — which can’t be ruled out — might.Either way, Schneider can’t afford to take the wrong turn. Not only is activist Dan Loeb still on the register, but Nestle’s valuation has increased significantly under his tenure. The shares trade on about 22 times forward earnings, compared with about 20 times for Unilever.The premium is justified by Unilever’s recent sales stumble, as well as its slower pace of portfolio change and less focused approach to acquisitions. That doesn’t mean Nestle won’t be punished if it disappoints in the same way as its rival.To contact the author of this story: Andrea Felsted at afelsted@bloomberg.netTo contact the editor responsible for this story: Melissa Pozsgay at mpozsgay@bloomberg.netThis column does not necessarily reflect the opinion of Bloomberg LP and its owners.Andrea Felsted is a Bloomberg Opinion columnist covering the consumer and retail industries. She previously worked at the Financial Times.For more articles like this, please visit us at bloomberg.com/opinionSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • Is It Too Late To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?
    Simply Wall St.

    Is It Too Late To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

    Let's talk about the popular Fresenius SE & Co. KGaA (ETR:FRE). The company's shares saw a double-digit share price...

  • If You Had Bought Fresenius SE KGaA (ETR:FRE) Stock Three Years Ago, You'd Be Sitting On A 34% Loss, Today
    Simply Wall St.

    If You Had Bought Fresenius SE KGaA (ETR:FRE) Stock Three Years Ago, You'd Be Sitting On A 34% Loss, Today

    While not a mind-blowing move, it is good to see that the Fresenius SE & Co. KGaA (ETR:FRE) share price has gained 20...

  • Does Fresenius SE & Co. KGaA (ETR:FRE) Have A Good P/E Ratio?
    Simply Wall St.

    Does Fresenius SE & Co. KGaA (ETR:FRE) Have A Good P/E Ratio?

    This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios...

  • Should You Be Pleased About The CEO Pay At Fresenius SE & Co. KGaA's (ETR:FRE)
    Simply Wall St.

    Should You Be Pleased About The CEO Pay At Fresenius SE & Co. KGaA's (ETR:FRE)

    Stephan Sturm has been the CEO of Fresenius SE & Co. KGaA (ETR:FRE) since 2016. First, this article will compare CEO...

  • Fresenius beats third-quarter forecasts with strong sales of home dialysis treatments
    Reuters

    Fresenius beats third-quarter forecasts with strong sales of home dialysis treatments

    The group said both Fresenius Medical Care <FMEG.DE>, the world's largest provider of dialysis treatments, and drugmaker Kabi saw strong organic growth in Asia and Europe, more than offsetting weak U.S. markets. Shares in both Fresenius and Fresenius Medical Care were up about 4% in early trade on Tuesday. Analysts said investors were relieved that a summer slowdown at Helios and a further negative impact from a U.S. dialysis treatment coordination programme known as ESCO did not materialize.

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more